Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
BioVersys AG ( (CH:BIOV) ) just unveiled an update.
BioVersys AG has announced the granting of a crucial patent in China for its BV100 drug candidate, a novel intravenous formulation of rifabutin designed to treat infections caused by the Acinetobacter baumannii-calcoaceticus complex, including carbapenem-resistant strains. This patent, now secured in over 25 countries, strengthens BioVersys’ market position as it prepares to initiate a Phase 1 clinical trial in China, aiming to address the high incidence and resistance rates of Acinetobacter infections in the region, with a global sales potential of USD 800 million.
More about BioVersys AG
BioVersys AG is a clinical stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of novel antibacterial products targeting serious infections caused by multidrug-resistant bacteria. The company leverages its internal technology platforms to create treatments that address unmet medical needs in the antimicrobial and microbiome fields, focusing on nosocomial infections and tuberculosis.
YTD Price Performance: 2.13%
Average Trading Volume: 7,805
See more insights into BIOV stock on TipRanks’ Stock Analysis page.